Welcome to our dedicated page for Cardiff Lexingto SEC filings (Ticker: CDIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardiff Lexington Corporation (CDIX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory documents, along with AI-powered summaries to help interpret complex disclosures. As a Nevada-incorporated healthcare holding company and smaller reporting company, Cardiff Lexington files registration statements, current reports, and periodic reports that describe its operations, capital structure, and risks.
Investors can review Form S-1 filings, such as the registration statement filed in December 2025 in connection with a proposed public offering and planned uplisting of CDIX to The Nasdaq Capital Market. The S-1 includes detailed financial statements, risk factors, information on preferred and common stock, and the company’s description of its business as a targeted healthcare holding company focused on orthopedic, spine care, and pain management clinics through Nova Ortho and Spine, LLC.
Form 8-K current reports are also available, including filings that document material corporate events. For example, a January 2026 Form 8-K records the resignation of Daniel Thompson from the Board of Directors, notes that his departure was not due to any disagreement with the company, and confirms the appointment of Chief Executive Officer Alex Cunningham as Chairman of the Board. These filings provide authoritative detail on governance changes and other significant developments.
Through this page, users can track quarterly and annual reports (Forms 10-Q and 10-K, when filed) to analyze Cardiff Lexington’s revenue, gross profit, operating income, interest expense, mezzanine equity, preferred stock series, and accumulated deficit. AI-generated highlights help clarify key sections, such as segment information related to Nova Ortho and Spine, non-GAAP reconciliations referenced in earnings materials, and discussions of liquidity and capital resources.
In addition, the filings page surfaces insider and capital markets-related disclosures where applicable, allowing users to monitor how Cardiff Lexington manages its capital structure, including reverse stock splits and line-of-credit arrangements discussed in its public documents. Real-time updates from EDGAR, combined with AI explanations, make it easier to understand the implications of new filings for CDIX shareholders and prospective investors.
Staley Louis Jack Sr. reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Lexington Corp director Staley Louis Jack Sr. received a grant of 5,000 shares of Common Stock as a restricted stock award on April 1, 2026. The award was granted at a price of $0.00 per share as equity compensation, not an open-market purchase. The shares are scheduled to vest in equal installments quarterly over four quarters starting July 1, 2026, contingent on his continued service under the company’s 2024 Equity Incentive Plan. Following this grant, he beneficially owns 11,668 shares of Common Stock directly.
Pennington Catherine B. reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Lexington Corp director Catherine B. Pennington received a grant of 5,000 shares of Common Stock as a restricted stock award under the company’s 2024 Equity Incentive Plan. The award vests quarterly over four quarters starting on July 1, 2026, subject to her Continuous Service.
Following this compensation-related grant, Pennington holds a total of 11,668 shares of Cardiff Lexington common stock directly. The grant was recorded at a price of $0.0000 per share, reflecting an equity award rather than an open-market purchase.
Johnson Gillard B. III reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Lexington Corp director Johnson Gillard B. III received a grant of 5,000 shares of Common Stock as a restricted stock award under the company’s 2024 Equity Incentive Plan. These shares will vest in four quarterly installments starting on July 1, 2026, contingent on his continued service. Following this compensation-related award, he directly holds 11,668 shares of Common Stock.
Cardiff Lexington Corporation is offering 1,739,130 shares of common stock based on an assumed public offering price of $3.45 per share. The prospectus states net proceeds are expected to be approximately $4.9 million, or $5.7 million if the underwriters exercise the full over-allotment option.
The offering is contingent on the company’s application to list its common stock on Nasdaq. The company implemented a 1-for-3 reverse stock split on January 12, 2026, and financials for the year ended December 31, 2025 are included; revenue was $11,535,577 and net loss was $(5,507,592).
Cardiff Lexington Corporation files its annual report describing a healthcare-focused holding company with all current revenue from Nova Ortho and Spine clinics in Florida and Georgia and a small, non‑operating real estate subsidiary, Edge View Properties.
The company’s auditor includes a going concern warning, citing an accumulated deficit of $79,490,980 and negative operating cash flow of $2,853,274 for the year ended December 31, 2025. Management estimates its eleven clinics are running at about 35% capacity, with 270–375 patients per month, and is pursuing organic growth and acquisitions.
The model relies on plaintiff-related orthopedic care with accounts receivable typically collected over 12–24 months, leading to liquidity strain and dependence on external financing. Management believes it may need $5–10 million of additional capital to execute its acquisition strategy.
Cardiff Lexington Corporation amended the terms of its Series N Senior Convertible Preferred Stock. The company filed a Certificate of Amendment in Nevada that eliminates the prior redemption provisions, which had allowed the company to optionally redeem the shares and had given holders a mandatory redemption right in certain situations.
The change was approved by the required holders of the Series N preferred shares, meaning the investor group in that class consented to removing these redemption features. The amendment is attached as an exhibit, providing the full, updated terms of the Series N Senior Convertible Preferred Stock.
Cardiff Lexington Corp’s chief executive officer and director Alex H. Cunningham converted a large deferred pay balance into equity. On January 29, 2026, deferred compensation of $2,365,242 owed to him by the company was cancelled in exchange for 556,528 shares of common stock at $0 per share.
After this transaction, Cunningham directly beneficially owned 3,914,230 shares of common stock, and an additional 889,398 shares were held indirectly through the Alexander Hunt Cunningham, Sr. Revocable Trust.
Cardiff Lexington Corporation filed Amendment No. 2 to its S-1 registration statement. The company states this amendment is being made solely to file additional and updated exhibits listed in Item 16, such as a form of underwriting agreement, various preferred stock designations, warrant forms, loan and security agreements, employment and equity incentive plan documents, and legal opinions related to the shares and representative’s warrant. The preliminary prospectus in Part I and the remainder of Part II of the original registration statement remain unchanged and are omitted from this amendment. The filing also restates standard undertakings regarding indemnification under the Securities Act and is signed on behalf of the company by Chief Executive Officer and Chairman Alex Cunningham and other officers and directors.
Cardiff Lexington Corporation is conducting a primary offering of 1,500,000 shares of common stock, based on an assumed public offering price of $4.00 per share. The company’s stock now trades on the OTCQB under “CDIX,” and the closing of this offering is contingent on its common stock being approved for listing on The Nasdaq Capital Market under the same symbol.
At the assumed price, Cardiff Lexington expects to receive net proceeds of about $4.9 million, or $5.7 million if the underwriters fully exercise their 15% over-allotment option, which it plans to use to repay certain debt and for working capital and general corporate purposes. A recent 1‑for‑3 reverse stock split reduced outstanding shares from 41,152,612 to 13,718,365, and the company expects 16,361,362 shares outstanding after the offering, including automatic conversion of certain preferred stock and 200,000 shares issued to its financial advisor.
Cardiff Lexington is a healthcare-focused holding company whose revenue comes entirely from Nova Ortho and Spine, LLC, generating $8.27 million in 2024 and $8.76 million for the nine months ended September 30, 2025. Despite this, it recorded a net loss of $3.30 million in 2024 and $2.82 million for the first nine months of 2025, and its auditor issued a going concern paragraph, citing an accumulated deficit of $76,533,799 as of September 30, 2025. The company’s plaintiff-focused model creates an 18–24 month receivables collection cycle, pressuring liquidity and increasing reliance on external financing.
Cardiff Lexington Corp Chief Financial Officer granted restricted stock. On January 13, 2026, CFO Matthew T. Shafer received a restricted stock award of 62,500 shares of Cardiff Lexington common stock under the company’s 2024 Equity Incentive Plan at a grant price of $0 per share. Of this award, 31,250 shares vested immediately on the grant date, while 15,625 shares are scheduled to vest on January 2, 2027 and another 15,625 shares on January 2, 2028, conditioned on his continuous service with the company. Following this equity grant, Shafer directly beneficially owned 74,168 shares of Cardiff Lexington common stock.